{"entity":{"id":"nct05132075","kind":"trial","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","aka":["KontRASt-02"],"tldr":"A phase 3 trial testing JDQ443 in non-small-cell lung cancer, active and no longer recruiting.","summary":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05132075, led by Novartis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. Planned enrolment is 95 participants (actual). The study started in 2022-06-15 and primary completion is expected in 2026-08-25. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05132075","url":"https://clinicaltrials.gov/study/NCT05132075"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["jdq443"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05132075","phase":"3","setting":"A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT05132075","source":"https://clinicaltrials.gov/study/NCT05132075","fetchedAt":"2026-10-07T16:53:34.728Z","studySha256":"0976447bee155bfd30bbf911233b11ebf535246eb341896884cab7fdb8d2f3db","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"100 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":95,"enrolmentType":"ACTUAL","siteCount":51,"recruitingSiteCount":0,"countries":["Argentina","Australia","Canada","China","Finland","Greece","Hong Kong","Hungary","Iceland","India","Italy","Jordan","Lebanon","Malaysia","Mexico","Portugal","Romania","Slovenia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United States","Vietnam"]}],"started":"2022-06-15","startedType":"actual","enrolled":95,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05132075/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}